The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...

When the symptoms and inflammation are not brought under control, they can cause organ damage. Like other cell therapies, CAR T cell therapy uses a modified cell either from the patient or from a ...

Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that ...

CAR-T Therapy Won't Raise Odds for a Second Cancer, Study Finds By Ernie Mundell HealthDay Reporter WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- Contrary to a warning placed on labels for CART-T ...

Chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, is one type of immunotherapy. Sometimes likened to a “smart drug” or “living drug,” CAR-T cell therapy relies on ...

Bottom Line: The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs ...

Early data suggest chimeric antigen receptor (CAR) T-cell therapy can achieve meaningful long-term results. A novel cell therapy that first emerged as a treatment for hematological malignancies ...

Bottom line: The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs ...

Overall, 5.8% of patients developed the new cancers. Four of the trials compared outcomes for patients who received CAR-T therapy versus standard regimens. Rates of secondary cancers were similar ...

HOUSTON — Chimeric antigen receptor T-cell therapy (CAR T) has emerged as a game changer for the treatment of multiple myeloma (MM), but questions remain as to how — and when — the ...

WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- Contrary to a warning placed on labels for CART-T cancer therapies, use of ...

Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clinical Cancer Research , 2024; DOI: 10.1158/1078-0432.CCR-24-1798 ...